Last reviewed 2026-04-23 · How we verify

ASP1707

ASP1707 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.

ASP1707 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Treatment of autoimmune diseases.

At a glance

Mechanism of action

By inhibiting these enzymes, ASP1707 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases.

Approved indications

• Treatment of autoimmune diseases

Common side effects

• Adverse event name

Key clinical trials

• A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis (PHASE1)
• A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain (PHASE2)
• A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate (PHASE2)
• A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects (PHASE1)
• A Study to Assess the Interaction Between ASP1707 and Itraconazole in Healthy Female Subjects (PHASE1)
• A Study to Assess the Effects of Single Ascending Doses of ASP1707 in Healthy Young Japanese Male Subjects (PHASE1)
• A Study to Evaluate the Effect of ASP1707 on the Bodies of Healthy Male Subjects After a Single Dose of Radioactive ASP1707 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.